logo-loader
viewOpen Orphan PLC

Open Orphan: Focused on a buoyant outlook

Open Orphan (ORPH) is a specialist Contract Research Organisation (CRO) offering pharmaceutical services relating to orphan and emerging therapies, and is pioneer in the testing of vaccines and anti-viral treatments through the use of human viral challenge (HVC) studies. FY19 financial results reflected a period of transition, as the company consolidated only six months of Venn revenues, with the focus being on integration and ongoing streamlining of the business, following the post–period acquisition of hVIVO in January. The outlook is for expanding its range of pharma services, completing the development of a COVID-19 HVC model, which is already attracting the attention of global pharma industry. It is also based on leveraging the potential of the broader anti-viral challenge study capabilities, and a growing range of laboratory services, targeting profitability by Q3 2020.

 

Quick facts: Open Orphan PLC

Price: 25 GBX

AIM:ORPH
Market: AIM
Market Cap: £164.52 m
Follow

What's in the report?

Financial results and forecasts
Growth drivers
Management
Market conditions
Milestones & inflection points

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

LEGAL NOTICE – IMPORTANT – PLEASE READ:

Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...

FOR OUR FULL DISCLAIMER CLICK HERE

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

Watch

Open Orphan: Sustaining commercial traction

Proactive analyst Emma Ulker talks to Proactive London about Open Orphan (LON:ORPH). Ulker talks through the prospects for the specialist pharmaceutical services company, which is the world leader in the testing of vaccines and antivirals using human challenge studies. Ulker believes Open...

2 weeks ago

3 min read